Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 254

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 254
---
 2024 and for the six -monthperiod ended December 31, 2024, respectively. (4)To reflect the elimination of interest costs of borrowings provided by the Parent to OmnigenicsAI and Heritas Argentina, due to the capitalization of said liabilities described in Note (6) under “ Adjustments to Unaudited Pro Forma Combined Statement of Financial Position as of December 31, 2024.”The eliminated interest expense corresponds to the accrual in OmnigenicsAI’s combined financial statements corresponding to said capitalized loans. (5)Represents the interest expense corresponding to intercompany loans agreements with OmnigenicsAI’s parent companies for the twelve -monthperiod ended June 30, 2024 and for the six -monthperiod ended December 31, 2024, that would have accrued if such financings had been obtained on July 1, 2023 and July 1, 2024, respectively. See Note (5) under “ Adjustments to Unaudited Pro Forma Combined Statement of Financial Position as of December 31, 2024” section for details.

109 Adjustments to Unaudited Pro Forma Combined Statement of Financial Position as of December 31, 2024 The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows: (1)To reflect the release of cash from marketable securities held in the Trust Account together with the Accrued interest receivable in each redemption scenario. For scenario1, which assumes no redemption of Public Shares, no release of cash is reflected. For scenario 2 the 50% redemption of Public Shares, reflects the corresponding release of cash. For scenario 3 the 100% redemption of Public Shares, reflects corresponding release of cash for the entire amount held within the Trust Account. It also includes additional Company Shares issued to Theo I SCSp pursuant to the Backstop Agreement and assumes the obligations under the Backstop Agreement are satisfied through a cash contribution to OmnigenicsAI up to $10,000,000 in an amount that exceeds the aggregate amount of cash on deposit in the Trust Account (including any interest earned on the funds held in the Trust Account) remaining after payment in full of the SPAC Shareholder Redemption Amount, relative to each respective scenario, considering a price of $10 per share. See “ Certain Agreements Related to the Business Combination — Backstop Agreement.” Contributions performed under the Backstop Agreement were calculated as disclosed below: (a